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LETTER
NOTES & COMMENTSCommentary on ‘‘A new drug with
a nasty bite: A case of krokodil-
induced skin necrosis in an
intravenous drug user’’To the Editor: In a recent article in JAAD Case
Reports, Haskin and colleagues1 implicate kro-
kodil as the cause of skin lesions in a young
woman with ongoing intravenous drug abuse.
The only evidence supporting krokodil as the
cause is the history from the patient. With no
analytical confirmation, either from bodily
fluids from the patient or from the injected
substance, it is difficult to accept that krokodil
(illegally synthesized desomorphine) caused the
lesions in question. There are no substantiated
cases of krokodil use in North America, despite
a flurry of lay media reports in 2013 and one
similarly unsubstantiated case report here in
Saint Louis.2
The US Drug Enforcement Agency’s 2014
Drug Threat Assessment Report stated that ‘‘there are
no confirmed cases of krokodil abuse in the United
States.’’3 The 2015 report, released on November 4,
2015, had no further mention of krokodil.4
Levamisole, a common adulterant in cocaine, can
produce skin lesions similar to those described by
Haskin and colleagues.5-7 The US Drug Enforcement
Agency has found levamisole in some samples of
seized heroin.8 Likewise, soft-tissue infections and
contaminants in injected heroin can cause similar
findings.
With no objective proof of krokodil use and
with other possible explanations, we conclude
that it is unlikely that krokodil caused this
patient’s skin lesions. We assert that krokodil use
in the United States remains unproven and
unlikely.9,10ª 2016 by the American Academy of Dermatology, Inc. Published
by Elsevier, Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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